Mylan (MYL) Surges on DOJ EpiPen Medicaid Rebate Settlement
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- Twitter (TWTR) Tops Q3 EPS by 4c; Announces Restructuring, Workforce Reduction
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Mylan (NASDAQ: MYL) is trading up 9% after-hours Friday after the company it agreed to the terms of a $465 million settlement with the DOJ and other government agencies that will resolve questions that have been raised about the classification of EpiPen for purposes of the Medicaid Drug Rebate Program.
The company's 2016 guidance was also cut, but very little.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan Launches First Generics of Benicar® and Benicar HCT® Tablets
- CenturyLink (CTL) Pares Gains Following Merger Rumor, Up Less Than 10%
- tronc (TRNC) Trades Lower as Gannett (GCI) Deal in Doubt as Banks Withdraw Funding - Bloomberg
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!